Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The PD-1/PD-L1 interaction has emerged as a significant target in cancer immunotherapy. Current medications include monoclonal antibodies, which have shown impressive clinical results in the treatment of several types of tumors. The cocrystal structure of human PD-1 and PD-L1 is expected to be a valuable starting point for the design of novel inhibitors, along with the recent crystal structures with monoclonal antibodies, small molecules, and macrocycles.

Original publication




Journal article


Angew Chem Int Ed Engl

Publication Date





4840 - 4848


PD-1, PD-L1, antitumor agents, protein structures, protein-protein interactions, Antibodies, Monoclonal, Antineoplastic Agents, Immunological, B7-H1 Antigen, Drug Design, Humans, Immunotherapy, Ligands, Molecular Targeted Therapy, Neoplasms, Programmed Cell Death 1 Receptor